锚定乙型肝炎功能性治愈,构建中国特色乙型肝炎新药审评标尺OA

Achieving the functional cure(clinical cure)of hepatitis B is the primary goal of current clinical hepatology and novel drug research and development.In 2023,the Center for Drug Evaluation,National Medical Products Administration,issued Technical guidance for clinical trials of therapeutic drugs for chronic hepatitis B virus infection to establish a top-level regulatory framework.Supporting Q&A documents for public consultation were released in July 2026 to provide practical policy guidance for the research and development of novel hepatitis B drugs,which has far-reaching implications for clinical investigators,innovative pharmaceutical enterprises,and the development of hepatology.